Subsequent Events	12 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On January 10, 2025, the Company received an unsolicited, non-binding acquisition proposal from Biogen to acquire all outstanding shares of the Company not already owned by Biogen for $7.22 per share. On January 27, 2025, the Board of Directors (the “Board”) unanimously rejected the unsolicited, non-binding acquisition proposal received from Biogen. The Company further announced that the Board has initiated a process to explore strategic alternatives for the Company. On January 16, 2025, the Company commenced litigation against Biogen in the Delaware Court of Chancery seeking declaratory, injunctive and other relief. In its complaint, the Company alleges that Biogen breached the standstill provision in the Biogen Stock Purchase Agreement by making an unsolicited acquisition proposal and related public disclosures. See Note 6, Commitments and Contingencies, for further details.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/855/tableOfContent

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483399/855-10-50-2

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration